SCHEMBL2744233

SCHEMBL2744233

COc1cc(/C=C/C(=O)/C=C/c2ccc(OC)c(OC)c2)ccc1O

nearest known ligand 0.91

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.91
NFKB1 P19838 3/20 0.91
CYP1A2 P05177 2/20 0.91
ALOX5 P09917 2/20 0.91
HSD11B1 P28845 2/20 0.91
STAT3 P40763 2/20 0.91
NFKB2 Q00653 2/20 0.91
RELA Q04206 2/20 0.91
NFE2L2 Q16236 2/20 0.91
GLO1 Q04760 3/20 0.72
IKBKB O14920 1/20 0.72
CHUK O15111 1/20 0.72
IKBKG Q9Y6K9 1/20 0.72
CA2 P00918 3/20 0.72
APP P05067 3/20 0.72
KDM4E B2RXH2 3/20 0.72
CA12 O43570 2/20 0.72
CA1 P00915 2/20 0.72
CA3 P07451 2/20 0.72
PKM P14618 2/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2744234 1.00 CYP2D6 (0.91) CYP2D6NFKB1CYP1A2ALOX5HSD11B1
SCHEMBL1493283 0.95 CYP2D6 (1.00) CYP2D6NFKB1CYP1A2ALOX5HSD11B1
SCHEMBL30668505 0.95 CYP2D6 (1.00) CYP2D6NFKB1CYP1A2ALOX5HSD11B1
SCHEMBL29478095 0.95 CYP2D6 (1.00) CYP2D6NFKB1CYP1A2ALOX5HSD11B1
SCHEMBL1493282 0.95 CYP2D6 (1.00) CYP2D6NFKB1CYP1A2ALOX5HSD11B1
SCHEMBL2743877 0.92 NFKB1 (0.79) CYP2D6NFKB1CYP1A2ALOX5HSD11B1
SCHEMBL2743876 0.92 NFKB1 (0.79) CYP2D6NFKB1CYP1A2ALOX5HSD11B1
SCHEMBL30493821 0.92 NFKB1 (0.79) CYP2D6NFKB1CYP1A2ALOX5HSD11B1
SCHEMBL2744663 0.91 NFKB1 (0.74) CYP2D6NFKB1CYP1A2ALOX5HSD11B1
SCHEMBL19824721 0.91 CYP2D6 (0.91) CYP2D6NFKB1CYP1A2ALOX5HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100152493-A1 BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER SHIBATA, HIROYUKI (JP) 2010-06-17 US claimed
US-8178727-B2 Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer NATIONAL UNIVERSITY CORPORATION TOHOKU UNIVERSITY (JP) 2012-05-15 US disclosed
US-20100152493-A1 BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER SHIBATA, HIROYUKI (JP) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152493-A1 BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER MYC, CCNE2, CCNE1 CYP2D6 1871/4885NFKB1 328/4885CYP1A2 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.